Compare 10X Genomics Inc (TXG) vs Xcel Energy Inc (XEL) Price & Performance

10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.

TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.

Xcel Energy (XEL) trades at $72.42, down 0.43% with a bearish technical signal despite recent earnings beats. The stock shows solid fundamentals with $14.67B revenue, 15.28% net margin, and consistent cash flow growth. Analyst consensus is bullish with a $90.83 price target (62.96% buy rating), while institutional activity shows mixed positioning. Recent news highlights data center power demand growth and wildfire liability concerns.

XEL offers attractive utility exposure with 11% rate base growth potential and dividend stability, but faces regulatory and wildfire litigation risks. The current valuation at 20.1x P/E appears reasonable given earnings trajectory, though technical weakness near support at $71-72 requires monitoring for entry points.